DICE Therapeutics, Inc., a biopharmaceutical company, builds various oral therapeutic candidates to treat chronic diseases in immunology and other therapeutic areas. Its platform DELSCAPE, is designed to discover selective oral small molecules to modulate protein-protein interactions (PPIs) as effectively as systemic biologics. The company's lead therapeutic candidate is DC-806, an oral antagonist of the pro-inflammatory signaling molecule, interleukin-17, which is a validated drug target implicated in a various immunology indications. It is also developing oral therapeutic candidates targeting a4ß7 integrin for the treatment of inflammatory bowel diseases, as well as targeting aVß1/aVß6 integrin for the treatment of idiopathic pulmonary fibrosis. In addition, the company focuses on immuno-oncology for antibody therapeutics. The company was incorporated in 2013 and is headquartered in South San Francisco, California.
P/S ratio for DICE Therapeutics, Inc. (DICE)
P/S ratio as of 2022: 0.00
According to DICE Therapeutics, Inc.'s latest financial reports and stock price the company's current price-to-sales ratio (TTM) is 0.00. At the end of 2021 the company had a P/S ratio of 278.61.
P/S ratio history for DICE Therapeutics, Inc. from 2019 to 2022
P/S ratio at the end of each year
| Year | P/S ratio |
|---|---|
| 2022 | 0.00 |
| 2021 | 278.61 |
| 2020 | 992.80 |
| 2019 | 148.36 |